Company profile

Antengene Corporation Limited

6996 · HKEX (Clinical-stage APAC oncology biopharma, confirmed trading as HKEX: 6996 (multiple live quote sources). Sources: https://clinicaltrials.gov/study/NCT03944057 Entity resolved by asset-pipeline-v2.)

Public Market Listing

6996HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Antengene Corporation Limited are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Selinexor
Approved
XPO1 (exportin-1)Small molecule
Non-Small Cell Lung CancerMultiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.